Alkermes Plc news

   Watch this stock
Showing stories 1 - 10 of about 87   

Articles published

ALKS 45.03 +2.20 (5.14%)
price chart
Alkermes Plc Rating Lowered to Neutral at Zacks (ALKS)
Alkermes Plc logo Alkermes Plc (NASDAQ:ALKS) was downgraded by Zacks from an �outperform� rating to a �neutral� rating in a report issued on Wednesday, StockRatingsNetwork.
Related articles »  
Alkermes Plc (ALKS) Is Rising On Phase 3 Study Results
(RTTNews.com) - Alkermes plc ( ALKS ) announced positive topline results from a phase 3 clinical trial of aripiprazole lauroxil in patients with schizophrenia Tuesday morning.
Alkermes to seek schizophrenia drug approval after trial success  Chicago Tribune (blog)
Alkermes Announces Positive Topline Results From Pivotal Phase 3 Study of ...  MarketWatch
Related articles »  
Alkermes Plc Upgraded by Mizuho to Buy (ALKS)
Alkermes Plc logo Alkermes Plc (NSADAQ:ALKS) was upgraded by equities researchers at Mizuho from a �neutral� rating to a �buy� rating in a research report issued on Thursday, AnalystRatings.
Alkermes Plc's Outperform Rating Reaffirmed at Leerink Swann (ALKS)  Ticker Report
Alkermes Plc Rating Increased to Buy at Mizuho (ALKS)  Mideast Time
Related articles »  
Alkermes Plc Upgraded to �Buy� at Mizuho (ALKS)
Alkermes Plc logo Alkermes Plc (NASDAQ:ALKS) was upgraded by equities research analysts at Mizuho from a �neutral� rating to a �buy� rating in a research note issued to investors on Thursday, TheFlyOnTheWall.
Alkermes Plc CFO James Frates Sells 7000 Shares (ALKS)
Alkermes Plc logo Alkermes Plc (NASDAQ:ALKS) CFO James Frates sold 7,000 shares of the stock in a transaction dated Wednesday, April 9th.
Notable Movers - Alkermes Plc (NASDAQ:ALKS), Jazz Pharmaceuticals plc ...  Techsonian (press release)
Related articles »  
Investor's Alert � NPS Pharmaceuticals, Inc. (NASDAQ:NPSP), Alkermes Plc ...
Alkermes Plc (ALKS) posted that positive topline results from a randomized, double-blind, placebo-controlled phase 3 clinical trial of aripiprazole lauroxil in patients with schizophrenia.
Alkermes Plc CFO Unloads $327880 in Stock (ALKS)
Alkermes Plc logo Alkermes Plc (NASDAQ:ALKS) CFO James M. Frates sold 7,000 shares of the company's stock in a transaction that occurred on Wednesday, March 19th.
Reviewing the Top Health Care Equities -- Research on IntelliPharmaCeutics ...  PR Newswire (press release)
Related articles »  
Alkermes Plc Upgraded to �Buy� by Mizuho (ALKS)
Alkermes Plc logo Mizuho upgraded shares of Alkermes Plc (NSADAQ:ALKS) from a neutral rating to a buy rating in a research report sent to investors on Thursday morning, StockRatingsNetwork.
Alkermes Plc Upgraded to "Buy" by Mizuho (ALKS)  Zolmax
Related articles »  
Stocks in the Spotlight: Alkermes Plc (ALKS), Qunar Cayman Islands Ltd (QUNR ...
Alkermes Plc (NASDAQ:ALKS) shares advanced over 7 percent in the current trading session after the biopharmaceutical company announced that its experimental drug for the treatment of schizophrenia's symptoms met the main objective of lowering the ...
Healthcare unusual volume: Alkermes Plc (NASDAQ:ALKS), RadNet (NASDAQ ...
Alkermes plc (Nasdaq:ALKS) announced positive topline results from a randomized, double-blind, placebo-controlled phase 3 clinical trial of aripiprazole lauroxil in patients with schizophrenia.
Related articles »